news & resources

publications and posters

 

 

 

Peer-Reviewed Publications

PRV-031 (TEPLIZUMAB)

Herold KC et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. NEJM. Published online June 9, 2019.

Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016 Jul;8(8):889-906.

Hagopian W et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908.

Sherry N et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet. 2011;378(9790):487-497.

 

 

PRV-015

Syage JA et al. Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am J Clin Nutr. 2018;107(2):201-207.

Guandalini S et al. Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Dig Dis Sci. 2016;61(10):2823-2830.

Ettersperger J et al. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016 Sep 20;45(3):610-625.

Shah S et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014;109(9):1304-1311.

Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-234.

Malamut G et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. Clin Invest. 2010;120(6):2131-2143.

 

PRV-6527

Genovese MC et al. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. J Rheumatol. 2015;42(10):1752-1760.

Franze et al., Interleukin-34 sustains inflammatory pathways in the gut. Clin Sci (Lond). 2015 Aug;129(3):271-280.

von Tresckow B et al. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-1850.

Moore B et al. Tu2027 Treatment with the CSF-1 Receptor kinase (CSF-1R) Inhibitor JNJ40346527 Suppresses Murine Colitis. Gastroenterology. 2014:146(5):S-900-901.

Marshall D et al. Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis. Inflamm Bowel Dis. 2007;13(2):219-224.

 

 

PRV-3279

Franks SE et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45.

Veri MC et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 2010;62(7):1933-1943.

Su K et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007 Mar 1;178(5):3272-3280.

 

 

PRV-101

Dunne JL et al. Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia. 2019;62(5):744-753.

Hyöty H et al. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Rev Vaccines. 2018;17(12):1071-1083.

Sioofy-Khojine AB et al. Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia. 2018;61(5):1193-1202.

Stone VM et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61(2):476-481.

Laitinen OH et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes. 2014;63(2):446-455.

Oikarinen S et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 2014 Feb;63(2):655-662.

Romero JR. Pediatric group B coxsackievirus infections. Curr Top Microbiol Immunol. 2008; 323:223-329.